

Professor Sarah Finer is a clinician-scientist dedicated to improving diabetes care and reducing health inequalities affecting diverse and underserved communities. She is Professor of Clinical Diabetes at Queen Mary University of London and Consultant Diabetologist at Barts Health NHS Trust.

Her research spans clinical science, genetics, and health data, with a focus on translating genomic discoveries into equitable precision healthcare. With Prof David van Heel, she co-leads Genes & Health, one of the world's largest community-based genomics studies, involving more than 77,000 British Bangladeshi and Pakistani participants. Her team conducts interdisciplinary research into type 2 diabetes, aiming to ensure that advances in genomic medicine benefit populations that have historically been underrepresented in research.

Supported by a Wellcome Discovery Award, Professor Finer is currently investigating genetic variants that affect the accuracy of the HbA1c blood test, and the implications of these variants for people with, or at risk of, type 2 diabetes. This work is being undertaken through Genes & Health and Black Health Legacy, a study she co-leads to strengthen representation of Black, Black African, and Black Caribbean communities in UK health research.